MN Gene and Protein
Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).
1 - 19 . (canceled)
20 . A biologically active MN protein or MN polypeptide which comprises a site to which mammalian cells adhere in a cell adhesion assay.
21 . A protein or polypeptide which specifically binds to said site of claim 20 , to which mammalian cells adhere in a cell adhesion assay.
22 . An anti-idiotype antibody to a MN-specific antibody.
23 . An anti-idiotype antibody according to claim 22 wherein said MN-specific antibody is either the M75 monoclonal antibody secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128, or the MN12 monoclonal antibody that is secreted from the hybridoma MN 12.2.2, which was deposited at the American Type Culture Collection under ATCC No. HB 11647.
24 . An anti-anti-idiotype antibody to the anti-idiotype antibody according to claim 22 .
25 . An anti-anti-idiotype antibody to the anti-idiotype antibody according to claim 23 .
26 . An anti-anti-idiotype antibody according to claim 24 which is polyclonal.
27 . An anti-anti-idiotype antibody according to claim 25 which is polyclonal.
28 . An isolated MN nucleic acid that comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS: 110-115.
29 . An isolated MN nucleic acid according to claim 28 comprising the nucleotide sequence of SEQ ID NO: 115.